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Abstract
Background: During clotting, a thrombin cleaves
fibrinogen releasing fibrinopeptide A (FPA). FPA is
easily identified in serum using matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF)
mass spectrometry (MS). Using MALDI-TOF MS, we
observed multiple, progressively shorter fragments of
serum FPA. Following ambient incubation of serum,
variations in the content of FPA fragments occur over
time. Denaturation of a thrombin by heating the
serum sample appears to minimize this variation.
These observations suggest that intrinsic proteolytic
and peptidolytic activity is elevated in serum and
perhaps originates from the coagulation cascade
enzymes themselves, especially a thrombin.
Methods: Extrinsic addition of a thrombin to a subset
(3–30 kDa) of plasma proteins was carried out to
induce proteolysis and to examine the resultant pep-
tides to reveal a thrombin susceptible parent proteins.
One of these identified proteins, hemopexin, was
directly digested by a thrombin and the peptides
examined to confirm the observations from the initial
plasma protein digestion.
Results: Extrinsic addition of a thrombin to a subset
(3–30 kDa) of plasma proteins results in wide-spread
digestion of proteins unrelated to coagulation, reveal-
ing a substrate range encompassing more than fibrino-
gen. Direct digestion of one of these proteins, hemo-
pexin, by a thrombin confirms these observations.
Conclusions: The resulting peptides indicate broad
tolerance beyond the consensus R-G cleavage site of
fibrinogen; in fact, there appears to be no bias for the
amino acid following the R/K residue. These data sup-
port our hypothesis that the enzymatic activities
inherent to coagulation, or at least to thrombin, con-
tribute to destabilization of the protein and peptide
content of serum.
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Introduction
Blood is a key tissue that provides a wide array of
functions interacting with or perfusing every other
tissue or organ in the body (1, 2) and hence it has a
central role in diagnostics and research. Serum is a
fluid derivative of blood resulting from a proteolytic
clotting process followed by centrifugation to remove
solid (clot) materials, including cells and other poorly
soluble content. Plasma is the liquid portion of blood
from which the cells are removed (typically via cen-
trifugation), with blood collection generally requiring
chemical inhibition (e.g., via anti-coagulants) of the
clotting process. Both serum and plasma can be used
for biomarker discovery; however, serum is widely
used as a starting material for many diagnostic
assays (2). Many current diagnostics rely on the
measurement of highly characterized, stable protein
or peptide biomarkers. In a number of current studies,
blood is expected to be an enormous resource of new
protein or peptide biomarkers, but many of these are
expected to be either potentially labile or in low abun-
dance, complicated by the tremendous dynamic
range of blood protein concentration masking this
valuable, dilute content (1, 3, 4).
Coagulation or clotting is a proteolytically driven
process, involving a cascade of enzymes including
serine proteases, which lead to the formation of
‘‘solid’’ fibrin/platelet plugs (2, 5). The protagonist
coagulation enzyme, thrombin (EC 3.4.21.5), is a ser-
ine protease with trypsin-like specificity. It cleaves the
NH2 terminal ‘‘caps’’ of chains Aa and Bb of fibrino-
gen, releasing fibrinopeptide A (FPA) and fibrinopep-
tide B (FPB), and rapidly converting fibrinogen to
insoluble fibrin (6, 7).
From a biochemical perspective, the clotting pro-
cess itself seemingly has the potential to reduce the
suitability of serum for proteome analysis. We
hypothesize that coagulation not only has the intend-
ed outcome of clot formation, but also has the poten-
tial ability to degrade many of the other proteins in
the blood sample. In terms of ‘‘biomarker discovery’’,
this potential proteolysis could especially affect low
abundance proteins, and, in fact, could be an under-
lying cause for poor research outcomes due to pro-
teolytic destruction of potential protein and peptide
biomarkers. Thrombin cleavage of the Aa chain of
fibrinogen should result in release of the ‘‘cap’’ pep-
tide, known as FPA wFPA, (MHq) of 1536.7 Da in
matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS)x. However,
a series of truncated FPA, peptides are observed in
serum (that are not present in detectable levels in
plasma), suggesting abundant exopeptidase activity
in serum.
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Compared to plasma, the time from serum sample
collection to analysis is extended due to the time
needed for complete clotting (minimum 30 min) prior
to centrifugation (approximately 10 min). Thus, the
inherent nature of the sample prevents a true ‘‘time
zero’’ representation of blood proteins. This extended
time frame would further amplify any proteolytic
damage driven by coagulation. The less like the ‘‘in
vivo’’ state a sample becomes, the more difficult the
discovery of new biomarkers will be.
There are many examples of the effects of so-called
‘‘preanalytical variables’’ (time, sample variables, col-
lection variables, etc.) on analytical outcome, partic-
ularly for protein and proteomic studies (3, 8–11). A
recent perspective on the subject has been put for-
ward with specific focus on proteome analyses of
blood (12). Variations in cytokine levels within serum
vs. plasma have also been demonstrated (13). The
variability of the relative peptide intensities in serum,
under various conditions, has been observed using
MS, including attempts to harness alternative proteo-
lytically derived patterns of common peptides for
diagnostic purposes (3, 14, 15). This phenomenon,
that extrinsic fibrinopeptides can be degraded by
intrinsic enzymes within serum, was reported more
than three decades ago (6). The common theme in
these works is that control of potential variability
requires painstaking care, if it is controllable at all.
More recently suggested is the inherent need for sam-
ple stabilization by reducing intrinsic proteolytic activ-
ity in plasma with protease inhibitors, potentially
enabling better detection of labile endogenous pep-
tides, such as bradykinin (m/z 1060) (16).
The study we present here demonstrates two dis-
tinct enzymatic activities in serum that alter the pep-
tide and protein content of blood after collection.
First, we observe a significant amount of peptidolytic
activity in serum, evidenced by variations in the
observable peptides (using MALDI-TOF MS), as a
function of time following serum preparation. Sec-
ond, we demonstrate a broad ex vivo proteolytic
potential of a thrombin, extending beyond its pre-
sumed high ‘‘clinical’’ specificity for fibrinogen cleav-
age. Taken together, these data demonstrate
extensive direct and/or indirect thrombin-induced
proteolysis of the protein and peptide content of
serum.
Materials and methods
Human a thrombin (EC 3.4.21.5) was purchased from
Enzyme Research Labs (South Bend, IN, USA). 4-(2-Hydroxy-
ethyl) piperazine-1-ethanesulfonic acid (HEPES minimum
99%), Trypsin (EC 3.4.21.4, sequencing grade), and Tri-
FluoroAcetic acid (TFA minimum 99.5%) were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). Ammonium
hydroxide and ammonium bicarbonate were from Sigma
Chemical and a-cyano-4-hydroxycinnamic acid (HCCA) was
from Bruker Daltonics (Billerica, MA, USA). Reagent grade
water (G18.2 mV) was produced in-house.
Hemopexin, purified ()40%, minimum) from human plas-
ma, was purchased from US Biological (Swampscott, MA,
USA).
Blood collection
Blood was collected into serum wBD SST, Becton Dickinson
(Franklin Lakes, NJ, USA) part number 367988x or EDTA plas-
ma (BD Vacutainer part number 367525, K2EDTA) tubes,
using a Safety-Lok blood collection set (BD part number
367281) from five healthy subjects. Serum was allowed to
clot for 30–40 min at room temperature and then centrifuged
at 2500=g for 10 min (at room temperature). Plasma was
centrifuged (as above) within 10 min of collection. Serum
samples were aliquoted immediately following centrifu-
gation into fractions and handled as described below. Plas-
ma was aliquoted directly following centrifugation and either
frozen (–808C) or used immediately.
Sample preparation
Aliquots were placed on ice. Samples designated for thermal
inactivation were placed at 658C for 30 min in a heat block.
Following heating, samples were returned to ice to equili-
brate. Time 0 aliquots were removed and quenched with TFA
to a final concentration of 0.1% (v/v) (to reduce intrinsic pro-
teolysis by acidification) and frozen (–208C). For the remain-
ing time points, aliquots were removed at specified time
intervals and quenched as described above.
Peptides were removed from the quenched samples by
ultrafiltration through a Microcon YM10 (10K MW cut-off
filter, Millipore, Waltham, MA, USA) according to the manu-
facturer’s instructions. Collected peptides were cleaned and
processed for MALDI-TOF MS analysis using Zip-Tips C18
(Millipore) according to the manufacturer’s instructions.
A saturated solution (;10 mg/mL) of HCCA was prepared
(in 50% v/v acetonitrile with 0.1% v/v TFA) for the matrix and
1–2 mL was mixed with an equal volume of peptide sample
and spotted on a stainless steel MALDI target (Bruker Dal-
tonics) and air dried.
Sample analysis
For peptide analysis of serum samples using MALDI-TOF
MS, samples (spotted ns3) were analyzed using an Ultraflex
II MALDI-TOF MS instrument from Bruker Daltonics. Oper-
ating in reflectron, positive mode, the MS spectra of peptides
between 750 and 4000 m/z were collected in an automated
mode. To enable a qualitative comparison of samples, the
spectra were collected from each sample (total 3000 laser
shots) from 30 qualified spectra per sample spot (each 100
shots). Spectra were routinely calibrated against an external
control peptide mixture after every 4–6 samples. In our pro-
cesses, peak intensity within such spectra typically has a
coefficient of variation -20% (data not shown). Spectra were
normalized (where indicated) against an internal peak (m/z
1465.9 – des AlaFPA) which has been shown to have supe-
rior ionization properties in MALDI MS (17), allowing a more
accurate evaluation of various experimental conditions.
Spectra were processed by FlexAnalysis ver. 2.4 (Bruker
Daltonics) and reviewed manually. Several peptides were
chosen for sequencing by MALDI-TOF/TOF. Spectra were
processed by FlexAnalysis and peak lists were analyzed
using BioTools (Bruker Daltonics) to determine peptide
sequences.
For all TOF/TOF experiments, peptides (and parent pro-
teins) were identified by searching against the NCBInr data-
base using Mascot (Matrix Science, Boston, MA, USA).
Liquid chromatography (LC)-MALDI was performed using an
Agilent nano HPLC 1100 with chemstation software (Agilent
Technologies, Palo Alto, CA, USA), coupled to a Proteineer
FC (Bruker Daltonics) for MALDI spot deposition. LC-MALDI
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Table 1 FPA and FPA-derived peptides observed in serum.
m/z Length Sequence PTM Plasmaa Serum
905.6 9 FLAEGGGVR ND 20,240
1020.6 10 DFLAEGGGVR ND 31,465
1077.6 11 GDFLAEGGGVR 40 34,882
1206.7 12 EGDFLAEGGGVR 80 166,824
1263.7 13 GEGDFLAEGGGVR ND 65,365
1350.8 14 SGEGDFLAEGGGVR ND 94,222
1465.8 15 DSGEGDFLAEGGGVR 1400 235,010
1536.9 16 ADSGEGDFLAEGGGVR 900 18,297
1545.8 15 DSGEGDFLAEGGGVR phospho-S ND 20,395
1616.9 16 ADSGEGDFLAEGGGVR phospho-S ND 30,400
Thrombin cleaves fibrinogen yielding peptide m/z 1536.9 as the primary (full-length) cleavage product. Shorter fragments,
successively truncated from the amino terminus, are observed in serum, along with serine phosphorylation variants. TOF/
TOF MS confirms peptide sequences (data not shown). Comparison of FPA peptide intensities observed in plasma (EDTA)
and serum using MALDI MS are listed in the appropriate columns. ND indicates peptides that were not observed in plasma,
even after more sensitive LC-MALDI analysis. aDue to low intensities direct MALDI was not adequate for FPA peptide analysis
in plasma, therefore LC-MALDI was employed to visualize FPA peptides. PTM, post-translational modification.
MS data collection was performed using WARP-LC software
as described below.
Proteolytic activity assay of a thrombin
Low molecular weight (LMW) proteins (3)30 kDa) were col-
lected from plasma (effectively removing fibrinogen to pre-
vent clotting) by ultrafiltration, by passing the plasma first
through a 30-kDa filter (Microcon YM30) and then running
the effluent through a 3-kDa filter (Microcon YM3). The
retained fraction from the second filter was adjusted to pH
7.4 with HEPES/NH3OH. Proteolytic digestion was carried out
by adding a thrombin (10 U/mL final, approximately 1–2=
the level observed within a clot activated tube) or trypsin
(20 U final), and samples were incubated at room tempera-
ture or 378C. Sample analysis by LC-MALDI was conducted
as follows.
The resulting peptides were separated with an Agilent
1200 nano-HPLC using a Zorbax 300SB-C18 (5 mm),
5 mm=0.3 mm trapping column (Agilent Technologies, San-
ta Clara, CA, USA) followed by a Chromolith CapRod RP-
18 endcapped column (Merck, Darmstadt, Germany) with
dimensions of 150 mm=0.1 mm for separation. A gradient
elution was performed using 0.1% TFA in water (mobile
phase A) and 0.1% TFA in acetonitrile (mobile phase B) at
2 mL/min. The gradient used was as follows: hold B at 2%
for 7 min, then increase from 2% to 30% B over 30 min, then
increase B to 90% over 20 min. Eluted peptides were moni-
tored at 214 nm using an 80-nL flow cell.
Fractions were spotted onto a 400-mm AnchorChip (Bru-
ker Daltonics) every 15 s using the Proteineer FC (Bruker
Daltonics). Warp-LC software (Bruker Daltonics) was used
to automate the MS collection process, using MS methods
described above, and to create a peak list for MS/MS analy-
sis based on a signal/noise threshold of greater than 20, and
data were analyzed as above.
Partially purified hemopexin ()50% purity from human
plasma) was purchased from US Biological. This sample was
heat-treated (658C for 30 min) to eliminate any contaminating
proteolytic activity that might be present from this partially
pure starting material, and peptides were removed by ultra-
filtration (YM10 cutoff filter). The absence of peptides and
intrinsic proteolytic activity in the resulting hemopexin pre-
paration was demonstrated using MALDI MS, monitoring
both immediately and over time. Dilutions of prepared
hemopexin w2, 20, and 200 mg/mL in phosphate buffered
saline (PBS) pH 7.4x were digested with a thrombin (0.1, 1,
and 10 U each) for 16 h at 258C. The same dilutions of hemo-
pexin were digested with trypsin (1 mg) as a positive control.
Results
FPA peptides in serum vs. plasma
Thrombin cleaves fibrinogen to initiate clot formation
and results in release of soluble FP fragments. The
full-length FPA has the sequence (ADSGEGD-
FLAEGGGVR) and a MALDI wMHqx mass-to-charge
ratio (m/z) of 1536.94 (Table 1). This peptide also
exists in a phospho-serine form, FPA-P (ADp-
SGEGDFLAEGGGVR) resulting in an m/z of 1616.94.
Serum and plasma samples from five subjects were
analyzed for the presence of FPA peptides.
A series of progressively shorter peptides, sequen-
tially truncated from the amino terminus, are easily
observed in serum with direct MALDI analysis (Table
1). We were unable to observe similar peptides in
plasma (EDTA anti-coagulant) with direct MALDI. In
case ion suppression may have reduced or impeded
the detection of these truncated FPs in plasma, LC-
MALDI was employed to provide improved sensitivity
and a more consistent view of peptide content. In
general, LC-MALDI enabled the detection of more
peptides, including very small amounts of the shorter
FPAs observed in serum. Table 1 displays the FPA
peaks identified as well as their average peak inten-
sities in both serum (direct MALDI) and plasma (LC-
MALDI). The expected dramatic difference in serum
(high) vs. plasma (low) FPA concentration is evident,
since FPA is essentially a by-product of clot formation.
Direct MALDI analysis of serum revealed ten easily
identified FPA fragments. Peak intensity comparison
between plasma and serum is qualitative as different
methods were required to visualize them; however,
within plasma, essentially only the direct thrombin
cleavage product (m/z 1536.9) as well as the singly-
truncated des Ala peptide are obvious (refer to Table
1 for sequence), while two additional peptides (m/z
1077.6; 1206.7) were detected at much lower intensity
(Table 1). Peptide sequences from both direct MALDI
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Figure 1 The variability of FPA peptides observed within serum samples across a 2-h time course from five subjects is
graphically represented.
Light bars represent neat serum incubated at room temperature and sampled at 0, 15, 30, 60, and 120 min. Dark bars represent
heat-treated aliquots of those same neat serum samples (mentioned above) sampled at the same time points. Time 0 is
defined as immediately following clotting and initial centrifugation processes. The bar heights represent the average of inten-
sity change over time 0, with all time points and all samples being averaged together into one value, with associated standard
deviations as shown. Individual spectra were first normalized against the des Ala FPA peak m/z 1465.9. This simplified view
allows a quick visual assessment of the variability seen over time, with a clear trend toward reduced variability in the heat-
treated serum sample.
and LC-MALDI experiments were confirmed using
TOF/TOF MS sequencing analysis (data not shown).
Variation of observed peptides within serum
Previous studies have demonstrated that thermal
denaturation of a thrombin occurs rapidly and follows
first-order kinetics at temperatures above 548C
(18–20). Therefore, prior to time-course studies,
serum samples from five subjects were divided in two
sets, one of which was heated to 658C for 30 min
(maximum temperature and time allowing thermal
inactivation without causing denaturation-mediated
precipitation in the samples) in an attempt to reduce
the intrinsic proteolytic activity. Following this, each
serum set was subjected to incubation at room tem-
perature for various times up to 2 h, and processed
and analyzed by MALDI MS as described above. The
data, including all time points and all subjects, are
averaged into a single intensity for each unique FPA
peptide, with each point and associated error bar
intended to represent the variability of that particular
peptide across time and between subjects (Figure 1).
The 1465 m/z peptide was used to normalize the
MALDI spectra prior to acquiring the relative peptide
intensity and averaging the data. Examination of the
neat serum samples reveals a time-dependant varia-
tion in the observed peptidome, especially evident
with the high abundant FPA peptides. By comparison,
the heat-inactivated samples display a reduction in
variability in FPA content, consistent with the asser-
tion that heat would denature most proteolytic
enzymes and thus significantly reduce time-depend-
ent variability. Further, MALDI has an inherent signal
variability of as much as 20%, which may contribute
significantly to the observed FPA variability in heated
samples.
Broad proteolytic damage caused by thrombin
activity
To observe a more direct effect of the potential pro-
teolytic activity of a thrombin on blood proteins, spe-
cifically isolated from the effects of the entire
coagulation cascade, LMW proteins were isolated
from plasma and subjected to enzymatic proteolysis.
Either a thrombin or trypsin was added, the latter
serving as a positive control for intentionally intro-
duced proteolysis (standard ‘‘bottom-up’’ proteomics
protocols). Isolation of proteins between 3 and
30 kDa, prior to digestion, is important for two aspects
of this experiment: 1) fibrin is removed, so that the
plasma will not ‘‘clot’’ upon addition of thrombin, and
2) since we monitor the evolution of peptides as the
products of proteolysis, it is important to purge below
3 kDa, so that any peptides that are detected in the
final analysis should result primarily from the inten-
tionally induced enzymatic cleavage. The resulting
digestions were subjected to RP-HPLC for examin-
ation (Figure 2).
In Figure 2A, the peptides/proteins present in the
LMW are visualized at time 0, with the expectedly
minimal peptide content from the sample preparation
process described above. All of the chromatograms
display peptide separations from 10 to 60 min elution,
with this view omitting the large peak eluting at
approximately 70 min containing the bulk of the intact
proteins and large polypeptides. The resulting proteo-
lysis after 7 days incubation (Figure 2B) is visualized
by an increase in the number and intensity of peaks
seen on the HPLC chromatograph. As expected, the
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Figure 2 Examination of the in vitro proteolytic activity of a thrombin on plasma-derived proteins.
The low molecular weight (LMW) proteins (3–30 kDa) were isolated from plasma and subjected to in vitro proteolysis by a
thrombin or trypsin. Peptide content, both before and after intentionally introduced proteolysis, is evaluated simply by the
RP-HPLC chromatograms. (A) RP-HPLC separation of LMW proteome from plasma (EDTA) at time 0. Even after peptide deple-
tion, some peptide peaks are evident in the starting material, but this view provides an initial baseline. (B) The prepared
sample after dwelling for 7 days at room temperature (RT), without any added proteases. Some proteolysis is observed, with
this view serving as a stringent negative control for the extrinsic digestion. (C) Trypsin digestion, for 24 h, of the LMW
proteome. As would be expected, extensive proteolysis is evident. (D) a Thrombin digestion, for 24 h, of the LMW proteome.
A peptide population of similar complexity to that produced by trypsin is evident.
added proteases (Figure 2C and 2D) lead to vastly
increased peptide content. The results suggest that a
thrombin can digest blood proteins with a similar effi-
ciency to trypsin.
The effluent from these HPLC experiments was
spotted onto a MALDI target at 15 s intervals for
60 min, and peptides were detected in MS mode, with
parent ions selected based on their signal-to-noise
(S/N) for TOF/TOF analysis. Peptides that were iden-
tified following a thrombin digestion all have R or K
carboxyl termini as expected and sequence-based
determinations of the parent protein were made
(Table 2). The identified protein substrates are not
functionally involved in coagulation, thus demonstrat-
ing enzymatic activity of thrombin clearly outside of
its defined ‘‘specific’’ role within the clotting cascade.
Significantly, only four out of the 32 cleavage sites
represented by these peptides have the expected R-G
motif fitting the presumed ‘‘specificity’’ of a thrombin.
Further, included in these peptides are three instances
of missed R-G potential cleavage sites.
Thrombin digestion of hemopexin
Hemopexin (UniProtKB/Swiss-Prot-P02790) was
selected from the non-coagulation proteins identified
in Table 2 as a test case for validating the results of
that experiment. Dilutions of partially purified hemo-
pexin (from human plasma, )50% pure) were incu-
bated with 0.1, 1, or 10 U of a thrombin per mL for
16 h and the peptides were examined by MALDI MS.
In general, the same hemopexin peptides were gen-
erated at all three dilutions with all concentrations of
a thrombin, though not uniformly detected through-
out all replicates (data not shown). This single-sub-
strate experiment facilitates detection of more
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Table 2 Peptides evolved from a thrombin digestion of plasma proteins.
Protein (GenBank ID) Peptide(s) Score
Complement comp. C4A (gi±179674) K_VGGNSKGTLKVLR_T 388
K_SHALQLNNRQIR_G
R_NGFKSHALQLNNR_Q
R_NGFKSHALQLNNRQIR_G
R_QI LEEELQFSLGSKINVK_VRG
R_TLEIPGNSDPNMIPDGDFNSYVR_V
Lipoprotein CIII (gi±224917) K_TAKDALSSVQESQVAQQAR_G 301
K_HATKTAKDALSSVQESQVAQQAR_G
Kininogen-1 precursor (gi±125507) K_RPPGFSPFR_S 192
R_GHGLGHGHEQQHGLGHGHKFKIa
Hemopexin (gi±386789) K_NFPSPVDAAFR_Q 111
R_FDPV EVPPR_YRG
R_FDPV EVPPRYPR_DRG
PK-120 precursor (gi±1402590) R_QLGLPGPPDVPDHAAYHPFR_R 101
Unnamed protein (gi±36575) R_TSAGTRQPQFISR_D 82
Apolipoprotein E3 (gi±1942471) K_VEQAVETEPEPELR_Qb 70
KIAA1319 (gi±7243019) R_ERELRALKGALK_E 68
LC-MALDI MS, following the RP-HPLC traces shown in Figure 2, yields identification of the peptides listed above, and enough
sequence information to give highly confident identification of the parent proteins. All peptides display the expected R or K
carboxyl terminal residues (marked by underscore). Mascot scores are listed for the parent protein identification. aC-terminal
fragment. bN-terminal fragment.
Table 3 Digestion of hemopexin by a thrombin.
Peptide mass Position Missed cuts Peptide sequence
1129.65 379–386 1 R_RLWWLDLK_S
1220.60* 92–102 0 K_NFPSPVDAAFR_Qa
1268.67* 209–219 1 R_FDPV EVPPR_YaRG
1402.77 116–126 2 K_VWVYPPEKKEK_G
1442.77 103–115 1 R_QGHNSVFLIKGDK_V
1517.78 81–91 2 K_WDRELISERWK_N
1534.78* 90–102 1 R_WKNFPSPVDAAFR_Q
1555.79 78–89 2 K_SHKWDRELISR_W
1684.89* 209–222 2 R_FDPV EVPPRYPR_DaRG
1837.88 387–402 0 K_SGAQATWTELPWPHEK_V
1999.91 223–239 2 R_DVRDYFMPCPG HGHR_GbRG
2344.22 92–112 1 K_NFPSPVDAAFRQGHNSVFLIK_G
2441.29 103–123 2 R_QGHNSVFLIKGDKVWVYPPEK_K
2644.36 92–115 2 K_NFPSPVDAAFRQGHNSVFLIKGDK_V
Evolved peptides were identified by peptide mass fingerprinting. Peptides able to be confirmed by high-quality TOF/TOF
spectra are indicated by (*) after the determined mass. A count of missed or incompletely cut R/K potential cleavage sites is
provided. Note that only one cleavage site (marked with 1) out of the 28 detected cleavages has the ‘‘specific’’ R-G motif
typically associated with thrombin cleavage of fibrinogen. By contrast, there are three instances (underlined) that bear the
R-G motif but were not cleaved by thrombin. aThe three peptides identified from plasma protein digestion in Table 2. bPutative
thrombin recognition site R-G.
peptides generated by a thrombin digestion (Table 3),
and includes all of the hemopexin-derived peptides
detected from the plasma protein digestion (Table 2).
Consistent with Table 2, all peptides share either R or
K carboxyl termini, but seemingly lack any preference
for the other residue of the scissile bond. We again
note several missed R-G cleavage motifs. These tar-
geted results further support our hypothesis that the
substrate specificity of a thrombin is not limited to
coagulation related proteins.
Discussion
FPA peptides in serum
While the dominant presence of FPA is expected in a
serum sample, the abundance of truncated FPA frag-
ments in serum is a corollary feature (15). A direct
comparison of equal amounts of EDTA plasma failed
to reveal an equivalent FPA fragment profile, even
after applying the more sensitive LC-MALDI analysis,
suggesting generation of the truncation pattern is
itself unique to serum. In fact, it has been demonstrat-
ed that in vitro clotting of purified fibrinogen (from
human plasma) results in the release of four peptides,
A(FPA), AP(FPA-P), Y(des Ala FPA), and B (FPB). FPB
accounted for approximately one-half of the total
mass. The remaining peptides consisted of the three
FPA fragments: FPA –70%, FPA-P –20%, desAla FPA
–10% (21). Previous studies with fibrinogen have
demonstrated that phosphorylation of the Aa chain
serine, a post-translational modification occurring
prior to secretion from the liver (22–24), and removal
of the amino-terminal alanine from the Aa chain are
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regulated with respect to subject parameters, such as
age, trauma, or illness (24–27), and are in place on
fibrinogen prior to thrombin action (22–24). The low
levels of FPA present in EDTA plasma can be attrib-
uted to the expectedly minimal thrombin activity in
vivo and minimal ex vivo thrombin activation accom-
plished by calcium sequestration by EDTA. In serum,
however, thrombin derived FPA levels rise dramati-
cally due to clotting, as expected, but also, somewhat
surprisingly, NH2 terminal truncated FPA peptides
appear quite prevalently (Figure 1). This observation
leads us to hypothesize that the obvious presence of
amino-peptidase(s) activity may somehow be
increased, either directly or indirectly, by activation of
the clotting cascade, and may be adversely affecting
the stability of other proteins and peptides. The ami-
no-peptidase activity, seen here at the macro level,
will degrade proteins and/or peptides at various rates,
probably in a sequence-dependent manner, and both
high and low abundance proteins/peptides may be
susceptible to amino-peptidase degradation.
Variability of serum protein and peptide content
Serum is the liquid portion of a clotted blood sample.
Clots form due to an enzymatic cascade dominated
by proteases, including thrombin, but after clot for-
mation is complete, these enzymes largely retain their
proteolytic potential. Residual enzyme activity was
demonstrated by showing that the multiple FPA frag-
ments discussed above could be generated in vitro
from extrinsic FPA (full-length) by the in vivo enzymes
intrinsic to serum (6). In the current study, time-
course experiments were conducted to see if the
intrinsic proteolytic activity of serum can be moni-
tored by time-dependant changes in the observed
peptidome.
In fact, serum appears inherently variable as evi-
denced by MALDI MS spectra that were taken over
specific time intervals (summarized in Figure 1).
Unfortunately, previous reports have stated that the
des Ala FPA (m/z 1465.9) is ionized far better than the
full-length FPA (m/z 1536.9) (17) and thus is more
easily detected in MALDI MS, such that the relative
abundance of des Ala FPA cannot be judged by inten-
sity in MALDI spectra.
We hypothesized that if the time-dependent varia-
bility of serum was indeed due to intrinsic enzymatic
activity, that heating the samples, and thus denatur-
ing the enzymes (18–20), should reduce the time-
dependent variability in the samples. Previous studies
(18–20), confirmed by our own initial data (not
shown), indicate that 658C for 30 min was effective for
a thrombin denaturation. Therefore, aliquots of all
samples were heated to 658C for 30 min, and then
examined across another time-course experiment for
variations in the observed peptidome. Thermal treat-
ment seems to reduce the variability of FPA markers
in all subjects across the time-course observed, pre-
sumably reflecting reduced intrinsic protease activity
(Figure 1).
A more direct examination of the general proteo-
lytic activity of a thrombin was conducted by isolating
the LMW proteins (between 3 and 30 kDa) from plas-
ma. Importantly, this size-discriminated protein frac-
tion is depleted of fibrinogen, and therefore cannot
clot upon a thrombin addition, thus facilitating spe-
cific examination of any proteolytic activity of a
thrombin beyond its well-characterized and suppos-
edly ‘‘highly specific’’ role in clot formation (2, 5, 6,
21, 28). Figure 2 clearly demonstrates that a thrombin
activity results in significant plasma protein digestion,
in fact on the same scale as trypsin; the latter being
traditionally used for intentionally caused and exten-
sive protein degradation typical of ‘‘bottom-up’’ pro-
teomics experiments (29). Thrombin clearly exhibits
extensive proteolysis upon the blood proteome, bely-
ing the biological ‘‘specificity’’ of this protease.
Biologically, thrombin cleaves fibrinogen, removing
the N-terminal ‘‘caps’’ to unmask fibrin self-assembly
potential (7). Cleavage of the A chain occurs between
residues Arg16 and Gly17 thus releasing the 16 resi-
due FPA peptide (6). The perceived narrow substrate
range and clinically relevant ‘‘enzymatic specificity’’
of thrombin may possibly be attributed to the fact that
it cleaves only four of the 376 trypsin-susceptible sites
in fibrinogen (6, 28). With fibrinogen as a substrate,
thrombin activity appears specific to only R-G
sequences, but, unlike trypsin, thrombin has been
shown to release the amino-terminal arginine, in an
exopeptidase-like fashion, even if the arginine is NO2
protected (28).
Table 2 displays the list of peptides identified by
TOF/TOF sequencing, as well as the parent protein,
following digestion of the peptide-depleted LMW
plasma proteins with a thrombin (from Figure 2).
Essentially, these results demonstrate a bottom-up
proteomics experiment enabled by a thrombin
instead of trypsin. All peptides show the R or K car-
boxyl termini expected from a thrombin digestion.
Two features from this Table are notable. First, the
parent proteins listed are not functionally exclusive to
coagulation or fibrinolysis. This observation is consis-
tent with previous studies, where a thrombin is impli-
cated as a proteolytic agent in other biological
processes (30–32). Second, only a very few of the
cleavage sites match the R-G motif commonly expect-
ed for a thrombin, and there are a few missed R-G
sites included in the observed peptides. These data
demonstrate in vivo catalytic potential of a thrombin
as a surprisingly non-specific trypsin-like serine pro-
tease, lacking both the substrate specificity (toward
fibrinogen) and the sequence specificity (R-G sites)
often associated with the well-known clotting function
of a thrombin.
To further validate that a thrombin activity was
responsible for this observed degradation, plasma
purified ()50%) hemopexin was selected as a single
specific substrate. Peptide and protease-free hemo-
pexin was prepared, and incubated with increasing
amounts of a thrombin. The resulting peptides (Table
3) confirm that hemopexin is cleaved by a thrombin.
Importantly, this list includes the peptides already
detected from a thrombin digestion of the more com-
plex LMW plasma protein sample (Table 2), indicat-
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ing, by extension, that the other proteins were also
substrates for a thrombin. As before, the majority
of cleavage sites do not have the R-G motif, while
several R-G sites within the peptides were not
cleaved.
Conclusions
Unlike previous reports claiming the R-G cleavage
specificity of a thrombin (for fibrinogen) (21, 28), we
observed a much broader tolerance for residues on
the carboxyl side of the scissile bond. However, the
data suggesting a limitation to R-G cleavage specific-
ity must take into account the given experimental con-
ditions (21, 28). Some of the peptides we observed
derive from parent proteins with molecular masses
much higher than our ‘‘sieving’’ process (3–30 kDa)
should have allowed. This can be explained both by
mild imprecision of the filtration device, and, more
importantly, by proteolysis having occurred within
the starting EDTA plasma itself, resulting in large frag-
ments within the selected mass range (33).
Thrombin may have a broad spectrum role in cel-
lular responses. The presence of thrombin receptors
seems ubiquitous on cell membranes, and thrombin
itself (when binding to such) appears to mediate a
multitude of responses from cellular proliferation to
cytokine release (34). It is suggested that thrombin
activity is due to local synthesis of activators of the
‘‘prothrombinase complex’’, such as tissue factor VIIa
and g-glutamyl carboxylase, and possibly has a role
in folliculogenesis (34). Taken together, it would seem
that, in a biologically uncontrolled environment, such
as inside a blood collection tube, a thrombin can
induce a variety of biological processes, perhaps
especially in the presence of cells in whole blood or
residual cells in serum or plasma. The subsequent
proteolytic activity observed with substrates beyond
fibrinogen thus may become kinetically favorable
especially over prolonged periods in the tube. By
extension, it has also been suggested that the degree
of proteolysis is indicative of general health and the
peptides generated may have value in biomarker dis-
covery (14, 15, 35).
Our data suggest that the presence and activity of
a thrombin, directly or indirectly, decreases protein
stability, and thus reduces the utility of serum as a
source for protein biomarker discovery. Enzymes in
the clotting cascade, though specific in biological role,
have been shown to have promiscuous activity (4, 5,
30–32), outside their expected catalytic function. The
data presented here provide direct evidence of this
substrate promiscuity, acting broadly upon the pro-
tein and peptide content of the plasma/serum itself.
We provide evidence that serum sample variability
is influenced by intrinsic proteolysis (specifically a
thrombin) and can be reduced by heat inactivation. In
general, broader protease inhibition (using chemical
inhibitors) or inactivation by heat treatment may be
warranted in cases where sample stability is desired.
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